Stockreport

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold [Seeking Alpha]

Astria Therapeutics, Inc.  (ATXS) 
PDF The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial ba [Read more]